Similarly, a significant increase in levels of mesothelin in sera analyzed in normal subjects, subjects with benign disorders, and subjects with malignant ovarian tumors revealed that mesothelin could be a novel biomarker and that higher levels denote poor overall survival in patients following optimal debulking surgeryor who have advanced stage ovarian cancer [52]. Here, MSLN is linked to ovarian carcinoma.